ArticleScience (New York, N.Y.)2020
Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 298 papers.
0numbers the graph read from it
0cells of the map it votes in
298citing papers in PubMed
21.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
298 citing papers in PubMed, 411 citations in OpenAlex.
- Integrative scRNA-seq and scTCR-seq analyses decode dual TCR γδ T-cell characteristics in human and mouse.ImmunoHorizons · 2026Article
- Insights into the Mechanism of Action of Phosphoantigen Prodrugs on Vγ9Vδ2 T Cell Activation.ACS pharmacology & translational science · 2026Article
- γδ T cells and cancer.The Journal of clinical investigation · 2026Review
- Phosphoantigen-driven dissociation of butyrophilin oligomers activates γδ T cells.Cell discovery · 2026Article
- Review
- γδ T Cells at the Crossroads of Tuberculosis and COPD: From Early Immunity to Tissue Remodeling.International journal of molecular sciences · 2026Review
- A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection.Journal of hematology & oncology · 2026Article
- γδ T cells show distinct responses to CMV after stem cell transplantation.Journal of molecular medicine (Berlin, Germany) · 2026Article
- NanoBRET Saturation Analysis with a Novel HaloTag Ligand Reveals Butyrophilin Heteromeric Interactions Controlling γ9δ2 T Cell Activation.ACS chemical biology · 2026Article
- A temporal map of B cell diversification mechanisms in mice.Nature immunology · 2026Article
- Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal transduction and targeted therapy · 2026Review
- BTN3A1 regulate the function of Vγ9Vδ2 T cells through TCR signaling pathway in ovarian cancer.Journal of ovarian research · 2026Article
- Engineering Strategies for Allogeneic T Cell-Based Platforms in Cancer Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Harnessing the potential of γδ T cells through engineering and combination treatment for cancer therapies.Nature communications · 2026Review
- Engineering CAR-Vδ2 T cells to boost persistence and anti-tumor function.bioRxiv : the preprint server for biology · 2026Article
- Risk Haplotype of BTNL2 Predisposes Male Patients to NSTEMI: A Genetic and Functional Study.Research square · 2026Article
- γδ T cells at the interface of innate and adaptive immunity in cancer.Journal for immunotherapy of cancer · 2026Review
- Inhibitory NK receptor expression associates with altered antimalarial function of γδ T cells.PLoS pathogens · 2026Article
- Cell stress activates γ9δ2 T cells via endogenous phosphoantigens and butyrophilin complex dynamics.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Article
238 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 7 institutions in 4 countries.
Marc RigauDepartment of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0001-5978-1073
Simone OstrouskaOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia.ORCID 0000-0001-7582-3990
Thomas S FulfordDepartment of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria 3010, Australia.
Darryl N JohnsonDepartment of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria 3010, Australia.
Katherine WoodsOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia.ORCID 0000-0003-3474-3104
Zheng RuanDepartment of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria 3010, Australia.
Hamish E G McWilliamDepartment of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0003-3479-3419
Christopher HudsonLudwig Institute for Cancer Research, Melbourne -Austin Branch, Victoria 3084, Australia.ORCID 0000-0002-1420-6988
Candani TutukaOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia.ORCID 0000-0003-3344-4102
Adam K WheatleyDepartment of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0002-5593-9387
Stephen J KentDepartment of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0002-8539-4891
Jose A VilladangosDepartment of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0001-6771-8891
Bhupinder PalOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia.
Christian KurtsUniversity of Bonn, Bonn, Germany.ORCID 0000-0002-6620-2401
Jason SimmondsCSL Limited at the Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0003-1947-8701
Matthias PelzingCSL Limited at the Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010, Australia.
Andrew D NashCSL Limited at the Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010, Australia.
Andrew HammetCSL Limited at the Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0003-1330-7303
Anne M VerhagenCSL Limited at the Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010, Australia.
Gino VairoCSL Limited at the Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0002-6945-8672
Eugene MaraskovskyCSL Limited at the Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0003-3690-6253
Con PanousisCSL Limited at the Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010, Australia.
Nicholas A GherardinDepartment of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0003-4690-2571
Jonathan CebonOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia.ORCID 0000-0002-3898-950X
Dale I Godfrey *Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria 3010, Australia. auldrich@unimelb.edu.au andreas.behren@onjcri.org.au godfrey@unimelb.edu.au.ORCID 0000-0002-3009-5472
Andreas Behren *Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia. auldrich@unimelb.edu.au andreas.behren@onjcri.org.au godfrey@unimelb.edu.au.ORCID 0000-0001-5329-280X
Adam P Uldrich *Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria 3010, Australia. auldrich@unimelb.edu.au andreas.behren@onjcri.org.au godfrey@unimelb.edu.au.ORCID 0000-0002-6350-5976
CSL (United Kingdom) · GBAustralian Research Council · AULa Trobe University · AUThe University of Melbourne · AUBiotechnology Institute · USLudwig Cancer Research · AUUniversity of Bonn · DE
Funding
Australian Research Council
Abstract
Gamma delta (γδ) T cells are essential to protective immunity. In humans, most γδ T cells express Vγ9Vδ2
Indexed as
Antigens, CDAntigens, NeoplasmButyrophilinsCell Line, TumorHumansLigandsLymphocyte ActivationPhosphorylationProtein DomainsProtein MultimerizationReceptors, Antigen, T-Cell, gamma-deltaT-LymphocytesAntigens, CDAntigens, NeoplasmBTN2A1 protein, humanBTN3A1 protein, humanButyrophilinsLigandsReceptors, Antigen, T-Cell, gamma-deltaT-cell receptor Vdelta2, humanT-cell receptor Vgamma9, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.